Fig. 5: Anti-androgen therapy reduces TRIM36 expression. | Cell Death & Disease

Fig. 5: Anti-androgen therapy reduces TRIM36 expression.

From: TRIM36, a novel androgen-responsive gene, enhances anti-androgen efficacy against prostate cancer by inhibiting MAPK/ERK signaling pathways

Fig. 5

a RNA-seq database showing the TRIM36 expression reduced in the ten PCa tumors that were exposed to neoadjuvant hormone therapy compared with treatment-naive samples. b, c Bicalutamide and MDV3100 inhibit AR recruitment to the TRIM36 ARBS based on a ChIP assay. LNCAP and C4–2 cells were treated with R1881 (10 nM), R1881 + bicalutamide (Bic; 1 or 10 μM), or R1881 + MDV3100 (MDV; 1 or 10 μM) for 24 h. d, e Bicalutamide and MDV3100 inhibit the androgen-mediated upregulation of TRIM36. LNCAP and C4–2 cells were treated with CSS or R1881 (10 nM), R1881 + bicalutamide (Bic; 1 or 10 μM), or R1881 + MDV3100 (MDV; 1 or 10 μM) for 24 h, P < 0.01

Back to article page